Form 4: Emergent BioSolutions Director Sells Shares

Emergent BioSolutions Director Donald W. DeGolyer sold 7,844 shares of common stock at $8.6475 per share to cover tax obligations from vested RSUs.

Summary

• Donald W. DeGolyer, a Director at Emergent BioSolutions Inc. (EBS), reported a sale of common stock.
• The transaction involved the disposition of 7,844 shares.
• The shares were sold at a price of $8.6475 per share.
• The sale was conducted to satisfy tax obligations arising from the settlement of vested Restricted Stock Units (RSUs) on May 22, 2025.
• Following this transaction, DeGolyer beneficially owns 137,659 shares of common stock.
• The transaction date is listed as August 12, 2025, indicating a future planned sale, likely under a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The sale is for tax obligations from vested RSUs, a common and often pre-planned event, rather than a discretionary sale, which mitigates negative sentiment.

Positives

• The sale was specifically to cover tax obligations from vested RSUs, not a discretionary sale, which is a common and often pre-planned event for insiders.

Negatives

• An insider, a Director, sold 7,844 shares of common stock.
• The sale price of $8.6475 per share is noted.

Future Outlook

The filing indicates a pre-planned sale of shares on August 12, 2025, executed under a Rule 10b5-1(c) plan to cover tax obligations from RSUs that vested on May 22, 2025.

Industry Context

This Form 4 filing details an insider transaction specific to Emergent BioSolutions Inc. and does not inherently provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: The sale by a director, even for tax purposes, could be perceived negatively by some, though it's a routine event for RSU vesting.

Key Dates

Recommendation

The reported insider sale by a director is specifically for satisfying tax obligations from vested Restricted Stock Units (RSUs) and appears to be a pre-planned transaction under Rule 10b5-1(c). Such sales are common and generally not indicative of a change in management's outlook on the company's future prospects. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, leading to a 'hold' stance.

Keywords

Emergent BioSolutions, EBS, Insider Trading, Form 4, Stock Sale, Director, DeGolyer, RSU, Tax Obligation